Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1990-09-12
1993-02-16
Griffin, Ronald W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 43, 514 45, 514 44, 514 47, 514 48, 514821, 536 267, 536 276, A61K 3170
Patent
active
051871629
ABSTRACT:
Methods of preventing neural tissue damage caused by excitotoxicity due to increased release of excitatory amino acids by increasing extracellular concentrations of adenosine in and around the neural tissue are provided. These methods are especially useful in treating neurodegenerative diseases such as Parkinson's Disease, Alzheimer's Disease, Amyotrophic Lateral Sclerosis or Huntington's Disease.
REFERENCES:
Sonsalla, et al. "Role for Excitatory Amino Acids in Methamphetamine-Induced Nigrostrial Dopaminergic Toxicity" Science 243: 398-400 (1989).
Snyder, S. H. "Adenosine as a Neuromodulator" Ann. Rev. Neural Sci. 8: 103-124 (1985).
Marangos, et al. "Basic and Clinical Aspects of Adenosinergic Neuromodulation" NeuroSci & Biobehav. Rev. 9: 421-430 (1985).
Dunwiddie, T. V. "The Physiological Role of Adenosine in the Central Nervous System" Int. Rev. Neurobiol., 27: 63-130 (1985).
Phillis, et al. "A Potent Depressant Action of Adenine Derivatives on Cerebral Cortical Neurones" Europ. J. Pharmacol. 30: 125-129 (1975).
Dunwiddie, et al. "Sedative and Anticonvulsant Effects of Adenosine Analogs in Mouse and Rat" J. Pharmacol. and Exptl. Therapeut. 220: 70-76 (1982).
Radulovacki, et al. "Adenosine Analogs and Sleep in Rats" J. Pharmacol. Exptl. Therapeut. 228: 268-274 (1981).
Lee et al. "The Anticonvulsive Action of Adenosine: A Postsynaptic, Dendritic Action by a Possible Endogenous Anticonvulsant" Brain Res. 21: 160-164 (84).
Paterson, et al. "Transport of Nucleosides" Annals of the New York Academy of Sciences, vol. 255, p. 402 (1975).
Deckert, et al. "Adenosine Uptake Site Heterogeneity in the Mammalian CNS? Uptake Inhibitors as Probes and Potential Neuropharmaceuticals" Life Sci. vol. 42 pp. 1331-1345.
Londos, et al. "Adenosine Receptors and Adenylate Cyclase Interactions" Regulatory Function of Adenosine, pp. 17-32.
Carson et al. "Effect of Adenosine Deaminase Inhibition upon Human Lymphocyte Blastogenesis" Journal of Clinical Investigation V. 57, p. 274 (76).
Church et al. "Phencyclidine/Sigma Receptor Agonists: Anticonvulsant Properties Due To N-Methylaspartate (NMA) Antagonism?" Excitatory Amino Acid Transmission pp. 115-118 (1987).
Daval et al. "Protective Effect of Cyclohexyladenosine on Adenosine A.sub.1 -receptors, Guanine Nucleotide and Forskolin Binding Sites Following Transient Brain Ischemia: A Quantitative Autoradiographic Study" Brain Res. 491: 212-226 (1989).
Marangos, "Adenosinergic Approaches to Stroke Therapeutics" Med. Hypotheses 32: 45-49 (1990).
Helgason, "Blood Glucose and Stroke" Stroke, 19(8): 1049-1053 (1988).
LeMay et al. "Insulin Administration Protects Neurologic Function in Cerebral Ischemia in Rats" Stroke, 19(11): 1411-1419 (1988).
Markey et al. "The Pharmacology of the Parkinsonian Syndrome Producing Neurotoxin MPTP (1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine and Structurally Related Compounds" Medicinal Research Rev. 6(4): 389-429 (1986).
Reinhard et al. "A Rapid and Sensitive Assay for Tyrosine-3-Monooxygenase Based upon The Release of .sup.3 H.sub.2 O and Adsorption of 3H-Tyrosine by Charcoal" Life Sci., 39: 2185-2189 (1986).
Dragunow, et al. "Is Adenosine an Endogenous Anticonvulsant" Epilepsia, 26(5):480-487 (1985).
Fox & Kelly "The Role of Adenosine and 2'-Deoxyadenosine in Mammalian Cells" Ann. Rev. Biochem. 47:655-86 (1978).
Gruber, et al. "Levels of dATP in ADA-inhibited Human Peripheral Blood B and T Lymphocytes Cultured in Deoxyadenosine.sup.a " Annals of New York Acad. Sci. pp. 315-318.
Gruber Harry E.
Marangos Paul
Gensia Pharmaceuticals
Griffin Ronald W.
LandOfFree
Methods of treating neurodegenerative conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating neurodegenerative conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating neurodegenerative conditions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2148159